Adagrasib is a targeted cancer therapy that inhibits the KRAS G12C mutation, which is common in various cancers, particularly non-small cell lung cancer (NSCLC). It works by irreversibly binding to the KRAS G12C protein, preventing its activation and disrupting the downstream signaling pathways involved in tumor growth and survival.
Cleanchem is a trusted provider of premium pharmaceutical reference materials, specializing in Adagrasib and its associated compounds. Our catalog includes pharmacopeial and non-pharmacopeial Adagrasib impurities, metabolites, nitrosamine derivatives (N-NO compounds), and stable isotope-labeled products. These reference standards play a critical role in pharmaceutical R&D, supporting activities such as product formulation, ANDA and DMF submissions, quality assurance, analytical method development, and stability assessments.
All Adagrasib-related substances undergo comprehensive characterization and are delivered with complete Certificates of Analysis and supporting analytical documentation to ensure regulatory adherence. Upon request, we can offer EP/USP traceable standards. Our products are routinely re-evaluated to maintain consistent quality and performance.
English
Arabic
Chinese (Simplified)
French
Japanese
Portuguese
Russian
Spanish
